TBIQYR4349-Global Procalcitonin (CAS 56645-65-9) Market Research Report 2019

                                          
Procalcitonin (PCT) is a 116 amino acid residue protein with a molecular weight of approximately 13kDa. Procalcitonin is a peptide hormone mainly produced by the C cells of the thyroid and certain endocrine cells of the lung. Under normal expression conditions, procalcitonin is immediately cleaved into three specific fragments, an N terminal residue, calcitonin and katacalcin. It can be expressed in E. coli
Sepsis is a life-threatening organ dysfunction caused by an excessive host immune response to a serious infection. According to the Centers for Disease Control and Prevention (CDC), 1.6 million Americans suffered from sepsis in 2011, of which about 260,000 did not survive. PCT can play a critical role in addressing this clinical challenge and has become a key component of successful sepsis protocols across the U.S. and Europe. PCT levels increase precipitously in patients with severe bacterial infection. PCT is therefore an extremely important biomarker enabling specific differentiation between a severe bacterial infection and other causes of inflammatory reactions.
Expressed in E.coli, PCT can be used as a reagent to prepare calibrators for procalcitonin or calcitonin immunoassays.

The global procalcitonin market had reached 126.4 g in 2016 and is expected to increase reach 212.6 g by 2023. In terms of revenue, the global procalcitonin chloride market was valued 61.85 Million USD in 2016, and is estimated to be worth 92.27 Million USD by 2023. Overall, the procalcitonin products performance is positive with the global economic recovery.

The manufacture region is concentrated in USA, Europe, China and Japan, of which Europe is the largest region with the share 36.92% in 2016. The production shares of Europe, China and Japan were 23.07%, 19.12% and 6.43%.

The consumption share of North America, Europe, Asia Pacific were 26.73%, 28.27%, 35.77% in 2016. Asia Pacific is the main export region.

There are companies adding new capacities and aims at the cost and quality leadership which shall improve profitability. As the same time, companies are focusing on technological innovation, equipment upgrades, and process improvements, to reduce costs and improve quality. The competition in Procalcitonin market will become more intense.


The global Procalcitonin (CAS 56645-65-9) market is valued at 62 million US$ in 2018 is expected to reach 93 million US$ by the end of 2025, growing at a CAGR of 5.2% during 2019-2025.
This report focuses on Procalcitonin (CAS 56645-65-9) volume and value at global level, regional level and company level. From a global perspective, this report represents overall Procalcitonin (CAS 56645-65-9) market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan.
At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report.

The following manufacturers are covered:
    Thermo Fisher
    Roche Diagnostics
    bioMerieux
    HyTest
    BBI Solutions
    ProSpec
    Wondfo
    Ningbo Medicalsystem Biotechnology
    Wuhan Easy Diagnosis Biomedicine
    Snibe
    Vazyme Biotech
    Getein Biotech
    Hotgen Biotech
    Lumigenex
    Nanjing Norman Biological Technology
    Shanghai Medicine'nest Pharmaceutical
    Kitgen
    Beijing KeyGen
    Beijing Apis

Segment by Regions
    North America
    Europe
    China
    Japan

Segment by Type
    Procalcitonin Antigen
    Procalcitonin Antibody

Segment by Application
    Medical Industry
    Scientific Research